In overcoming P-glycoprotein (P-gp)-expressing doxorubicin resistance in breast cancer cells, the clinically approved P-gp inhibitor tariquidar and its derivatives restored doxorubicin accumulation and enhanced ICD, defined as an increase in CRT translocation and the release of HMGB1 and ATP [94]. This evidence concerns the gene CALR and breast cancer.